Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition
East, M. P.; Olivares-Quintero, J. F.; Okumu, D. O.; Mott, K. R.; Sprung, R. W.; Whitman, A. A.; Joisa, C. U.; Chen, X.; Zhang, Q.; Erdmann-Gilmore, P.; Mi, Y.; Malone, J. P.; Bhatia, S.; McCabe, I. C.; Xu, Y.; Sutcliffe, M. D.; Spears, P. A.; Zawistowski, J. S.; Perou, C. M.; Earp, H. S.; Carey, L. A.; Yeh, J. J.; Spector, D. L.; Stover, D.; Gomez, S. M.; Spanheimer, P. M.; Townsend, R. R.; Johnson, G. L.
Show abstract
Triple-Negative Breast Cancer (TNBC) is a clinical subtype where aberrant expression of receptor tyrosine kinases (RTKs) leads to the activation of the RAS-RAF-MEK-ERK pathway contributing to tumor progression. Therapies targeting components of the RAF-MEK-ERK pathway in TNBC have been disappointing due to rapid onset of adaptive reprogramming of the RTK landscape leading to pathway reactivation. To overcome the dynamic heterogeneity of RTK expression and their convergence in activating RAS, treatment with the pan-RAS(on) inhibitor daraxonrasib (RMC-6236), which inhibits RAS-GTP regulation of RAF kinases, inhibited proliferation independent of TNBC kinotype or oncogenic RAS mutation in three of four TNBC cell lines in vitro and two patient-derived TNBC xenografts in mice. Daraxonrasib in combination with the MEK inhibitor trametinib prevented reactivation of the RAF-MEK-ERK pathway observed with each inhibitor alone and further enhanced inhibition of tumor growth in TNBC cell lines and xenografts. Inhibiting pan-RAS(on) RAS-GTP, with daraxonrasib, alone or in combination with a MEK inhibitor, provides a new strategy for the treatment of TNBC that inhibits RTK activation of the RAS-RAF-MEK-ERK pathway and tumor proliferation.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context of ESR1 mutation 94%
- HIF-1 regulated TPM3 links hypoxia to motility and invasion beyond the hypoxic fraction in triple-negative breast cancer 94%
- Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors 92%
Similar papers in this journal
- Clinicogenomic characterization of inflammatory breast cancer 93%
- Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer 93%
- Clinical Validation of Digital PCR-based ctDNA detection for risk stratification in residual triple negative breast cancer: TRICIA trial results 92%
Similar papers in this journal
- Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer 93%
- EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition 93%
- CHD1 is a synthetic lethal vulnerability in MYC-driven breast cancer 92%
Similar papers in this journal
- MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer. 93%
- Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers 93%
- Immune gene expression profiling reveals heterogeneity in luminal breast tumors 92%
Similar papers in this journal
- Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer 90%
- Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype 90%
- Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.